One-glance verdict
Not enough data
Fair value unavailable
Not enough cash-flow history to value this one with our method.
Fundamentals snapshot
enVVeno Medical Corporation
NVNO · NCM · Healthcare · Medical Devices
Current price
$8.67
52-week range
$7.01 - $35.17
Market cap
$6.02M
Balance sheet
Healthy
-30.20x Concerning
Net cash $20.98M. Interest coverage shows how many times profit covers the interest bill.
What stands out
0 Rewards
2 Risks
0 rewards · 2 risks
- Risk Return on equity was -58.5% last year — the company lost money on shareholders' equity.
- Risk Insider ownership is only 8.2% (peer median: 11.6%).
What this company does
enVVeno Medical Corporation
enVVeno Medical is a company developing devices to treat venous disease, which is when veins have trouble sending blood from the limbs back to the heart. Their main product is a replacement valve that is surgically implanted in the leg, and they are also working on a version that doesn't require open surgery. The company is currently focused on testing its products in clinical trials (studies to test a new treatment's safety and effectiveness in people), so its future success depends on getting approval from health regulators to begin selling them.
How the company got here
enVVeno Medical was founded in 1999 as Hancock Jaffe Laboratories, initially focused on developing tissue-based medical devices for heart and blood vessel diseases. Over time, the company shifted its primary focus to treating venous diseases, which affect blood flow in the veins. A key turning point was the development of its VenoValve product, leading the company to rebrand as enVVeno Medical Corporation in October 2021 to better reflect its new strategic direction. The company is still in the clinical stage, meaning its products are being tested and are not yet available for sale to the public.
What it actually does
enVVeno Medical is working on solutions for a condition called Chronic Venous Insufficiency (CVI), a problem that occurs when the valves in the veins of the legs are damaged and don't close properly. This can cause blood to flow backward and pool in the legs, leading to pain, swelling, and in severe cases, skin ulcers. The company is developing artificial valves made from animal tissue (bioprosthetic tissue) to replace the damaged human valves and restore normal blood flow. These products are designed to be implanted in the leg to help push blood back up toward the heart.
VenoValve
This is the company's first key product, a replacement valve that is implanted through traditional open surgery. A surgeon makes an incision in the upper thigh to place the VenoValve into a major vein. The VenoValve is currently in the late stages of clinical trials (the process of testing new medical treatments in people to see if they are safe and effective) in the U.S. to gather data for potential approval. Because the company's products are still in development, it does not yet have significant revenue (the money a company earns from selling its products or services).
enVVe System
This is the company's next-generation product, designed to be a non-surgical option for patients. Unlike the VenoValve, the enVVe valve is delivered through a catheter (a thin, flexible tube) in a minimally invasive procedure that doesn't require a large surgical incision or an overnight hospital stay. This approach is expected to be suitable for a wider range of patients and be preferred by more doctors. The enVVe system is also in clinical trials and has received an Investigational Device Exemption (IDE) from the FDA, which allows it to be tested in patients.
What management is betting on now
The company's main focus is on successfully completing the crucial final stages of testing for both the VenoValve and the enVVe System. A top priority is gaining regulatory approval (the necessary permission from government agencies like the Food and Drug Administration, or FDA) to begin selling their products. Management is particularly focused on the enVVe system, which they believe could become a groundbreaking treatment for the millions of people suffering from severe CVI who currently have no effective options. They are also working to protect their inventions with patents, which prevent competitors from copying their technology.
Price history
How the share price has moved
—
Loading price history…
Earnings history
Last 8 quarters — what happened
Click any quarter to read the call summary and what the numbers say.
FY2024 Q3
$-4.29M
FY2024 Q4
$-5.11M
FY2025 Q2
$-3.72M
FY2025 Q3
$-4.39M
FY2025 Q4
$-3.44M
Revenue
—
Net income
$-3.60M
Diluted EPS
-5.37
Operating cash flow
$-3.55M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.85M
Diluted EPS
-5.89
Operating cash flow
$-3.24M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-3.74M
Diluted EPS
-32.28
Operating cash flow
$-3.44M
Free cash flow
$-3.44M
Fetching…
Sources
Revenue
—
Net income
$-4.54M
Diluted EPS
-0.23
Operating cash flow
$-4.39M
Free cash flow
$-4.39M
Fetching…
Sources
Revenue
—
Net income
$-6.69M
Diluted EPS
-0.33
Operating cash flow
$-3.71M
Free cash flow
$-3.72M
Fetching…
Sources
Revenue
—
Net income
$-4.50M
Diluted EPS
-0.22
Operating cash flow
$-4.02M
Free cash flow
—
Fetching…
Sources
Revenue
—
Net income
$-6.23M
Diluted EPS
-0.30
Operating cash flow
$-5.11M
Free cash flow
$-5.11M
Fetching…
Sources
Revenue
—
Net income
$-5.64M
Diluted EPS
-0.35
Operating cash flow
$-4.28M
Free cash flow
$-4.29M
Fetching…
Sources
Is it cheap or expensive?
Fair value — vs current price $8.67
We couldn't calculate a fair value right now.
Is it drowning in debt?
Healthy
Net cash $21.0M - more cash than debt. Interest coverage -30.2x.
Net debt
$-20.98M
Interest coverage
-30.20x
enVVeno Medical Corporation's profit covers its interest bill about 0.0 times over. which is weaker than most peers shown here and 5 peers sit below 1x, which is the danger zone where profit does not fully cover the interest bill.
Healthy
Worse cushion
Baseline
Better cushion
NVNO
BASELINE
enVVeno Medical Corporation
Total debt $505.00K Interest coverage -30.20x This is the baseline the peer rows are being compared against.
Total debt $90.00K Interest coverage -407.95x Neither company has much profit cushion over interest right now.
Total debt $29.43M Interest coverage -5.45x Neither company has much profit cushion over interest right now.
Total debt $0.00 Interest coverage -9.76x Neither company has much profit cushion over interest right now.
Total debt $1.82M Interest coverage -1,146.57x Neither company has much profit cushion over interest right now.
Total debt $11.41M Interest coverage -8.53x Neither company has much profit cushion over interest right now.
What you should know
The case for and against NVNO
0 Rewards
2 Risks
Rewards
Risks
-
Return on equity was -58.5% last year — the company lost money on shareholders' equity.
-
Insider ownership is only 8.2% (peer median: 11.6%).
The numbers
All the key metrics, grouped by purpose
Tap any ? icon to learn what it means.
Valuation
How expensive the stock looks
P/E (TTM)
—
Forward P/E
-1.39x
P/B
0.28x
P/S
—
EV/EBITDA
0.87x
PEG ratio
—
Profitability
How much profit each dollar creates
Gross margin
0.0%
Operating margin
0.0%
Net margin
0.0%
ROE
-58.5%
ROA
-36.7%
Health
Liquidity and balance-sheet strength
Debt / equity
0.02x
Current ratio
11.70x
Quick ratio
11.39x
Total debt
$505.00K
Total cash
$21.49M
Growth
How the business has been compounding
Revenue TTM
$31.24K
Revenue 5Y CAGR
-59.1%
EPS TTM
-24.97
EPS 5Y CAGR
—
Cash flow
How much cash the business throws off
Operating CF TTM
$-14.62M
Free CF TTM
$-15.57M
FCF margin
-49,844.8%
Dividend
Shareholder payout
Yield
—
Payout ratio
0.0%
Last ex-div date
—